Drug/polymer nanoparticles prepared using unique spray nozzles and recent progress of inhaled formulation

Asian Journal of Pharmaceutical Sciences

Volumn 9, Issue 5, 2014, Pages 236-243

  Ozeki, Tetsuya ^a   Tagami, Tatsuaki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Inhalation; Lung diseases; One step preparation of nanocomposite particles; Pulmonary drug delivery; Spray drying

Indexed keywords

DRUG; NANOCOMPOSITE; POLYMER; SMALL INTERFERING RNA; VACCINE;

AEROSOL; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; PNEUMONIA; REVIEW; SCALE UP; SPRAY DRYING; TUBERCULOSIS;

EID: 84910029979     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2014.06.005     Document Type: Review

References (52)

1. Rogueda P.G., Traini D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin Drug Deliv 2007, 4:607-620.
2. Rogueda P.G., Traini D. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opin Drug Deliv 2007, 4:595-606.
3. Chan H.K. What is the role of particle morphology in pharmaceutical powder aerosols?. Expert Opin Drug Deliv 2008, 5:909-914.
4. Ozeki T., Beppu S., Mizoe T., et al. Preparation of two-drug composite microparticles to improve the dissolution of insoluble drug in water for use with a 4-fluid nozzle spray drier. J Control Release 2005, 107:387-394.
5. Ozeki T., Beppu S., Mizoe T., et al. Preparation of polymeric submicron particle-containing microparticles using a 4-fluid nozzle spray drier. Pharm Res 2006, 23:177-183.
6. Mizoe T., Ozeki T., Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS Pharm Sci Tech 2008, 9:755-761.
7. Ohashi K., Kabasawa T., Ozeki T., et al. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release 2009, 135:19-24.
8. Ozeki T., Akiyama Y., Takahashi N., et al. Development of a novel and customizable two-solution mixing type spray nozzle for one-step preparation of nanoparticle-containing microparticles. Biol Pharm Bull 2012, 35:1926-1931.
9. Nishino Y., Kubota A., Kanazawa T., et al. Improved intestinal absorption of a poorly water-soluble oral drug using mannitol microparticles containing a nanosolid drug dispersion. J Pharm Sci 2012, 101:4191-4200.
10. World Health Organization Global tuberculosis report 2013: addressing the co-epidemics of TB and HIV 2013, vol. 6:68-74.
11. Muttil P., Wang C., Hickey A.J. Inhaled drug delivery for tuberculosis therapy. Pharm Res 2009, 26:2401-2416.
12. Hanif S.N., Garcia-Contreras L. Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front Cell Infect Microbiol 2012, 2:118.
13. Misra A., Hickey A.J., Rossi C., et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb) 2011, 91:71-81.
14. Sung J.C., Garcia-Contreras L., VerBerkmoes J.L., et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrobial Agents Chemother 2009, 53:1338-1343.
15. Garcia-Contreras L., Sung J.C., Muttil P., et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 2010, 54:1436-1442.
16. Ungaro F., d'Angelo I., Miro A., et al. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol 2012, 64:1217-1235.
17. Patomchaiviwat V., Paeratakul O., Kulvanich P. Formation of inhalable rifampicin-poly(L-lactide) microparticles by supercritical anti-solvent process. AAPS Pharm Sci Tech 2008, 9:1119-1129.
18. Scheffer G.L., Pijnenborg A.C., Smit E.F., et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002, 55:332-339.
19. Tseng C.L., Su W.Y., Yen K.C., et al. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
20. Lemarie E., Vecellio L., Hureaux J., et al. Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv 2011, 24:261-270.
21. Min R., Li T., Du J., et al. Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals. Can J Physiol Pharmacol 2008, 86:288-298.
22. Rodriguez C.O., Crabbs T.A., Wilson D.W., et al. Aerosol gemcitabine: preclinical safety and invivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv 2010, 23:197-206.
23. Meenach S.A., Vogt F.G., Anderson K.W., et al. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomed 2013, 8:275-293.
24. Meenach S.A., Anderson K.W., Hilt J.Z., et al. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci 2013, 49:699-711.
25. Roa W.H., Azarmi S., Al-Hallak M.H., et al. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 2011, 150:49-55.
26. Al-Hallak M.H., Sarfraz M.K., Azarmi S., et al. Distribution of effervescent inhalable nanoparticles after pulmonary delivery: an invivo study. Ther Deliv 2012, 3:725-734.
27. Otterson G.A., Villalona-Calero M.A., Hicks W. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:2466-2473.
28. Otterson G.A., Villalona-Calero M.A., Sharma S., et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 2007, 13:1246-1252.
29. Garbuzenko O.B., Saad M., Pozharov V.P., et al. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U. S. a 2010, 107:10737-10742.
30. Zarogoulidis P., Chatzaki E., Porpodis K., et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine 2012, 7:1551-1572.
31. Dhanda D.S., Tyagi P., Mirvish S.S., et al. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release 2013, 168:239-250.
32. Balfour-Lynn I.M., Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2012, 11:CD001915.
33. Pilcer G., Rosiere R., Traina K., et al. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci 2013, 102:1836-1846.
34. Stigliani M., Aquino R.P., Del Gaudio P., et al. Non-steroidal anti-inflammatory drug for pulmonary administration: design and investigation of ketoprofen lysinate fine dry powders. Int J Pharm 2013, 448:198-204.
35. Pomazi A., Buttini F., Ambrus R., et al. Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam. Eur Polym J 2013, 49:2518-2527.
36. Prota L., Santoro A., Bifulco M., et al. Leucine enhances aerosol performance of naringin dry powder and its activity on cystic fibrosis airway epithelial cells. Int J Pharm 2011, 412:8-19.
37. Russo P., Stigliani M., Prota L., et al. Gentamicin and leucine inhalable powder: what about antipseudomonal activity and permeation through cystic fibrosis mucus?. Int J Pharm 2013, 440:250-255.
38. Ungaro F., d'Angelo I., Coletta C., et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012, 157:149-159.
39. Wahjudi M., Murugappan S., van Merkerk R., et al. Development of a dry, stable and inhalable acyl-homoserine-lactone-acylase powder formulation for the treatment of pulmonary Pseudomonas aeruginosa infections. Eur J Pharm Sci 2013, 48:637-643.
40. Duret C., Wauthoz N., Sebti T., et al. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int J Nanomedicine 2012, 7:5475-5489.
41. Duret C., Wauthoz N., Sebti T., et al. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties. Int J Pharm 2012, 428:103-113.
42. Jaafar-Maalej C., Elaissari A., Fessi H. Lipid-based carriers: manufacturing and applications for pulmonary route. Expert Opin Drug Deliv 2012, 9:1111-1127.
43. de Jesus valle M.J., Garavis Gozalez J., Lopez F.G., et al. Pulmonary disposition of vancomycin nebulized as lipid vesicles in rats. J Antibiot 2013, 1-5.
44. Lu D., Hickey A.J. Pulmonary vaccine delivery. Expert Rev Vaccines 2007, 6:213-226.
45. Garcia-Contreras L., Awashthi S., Hanif S.N.M., et al. Inhaled vaccines for the prevention of tuberculosis. J Mycobac Dis 2012, an open access journal (ISSN: 2161-1068). 10.4172/2161-1068.S1-002.
46. Tonnis W.F., Kersten G.F., Frijlink H.W., et al. Pulmonary vaccine delivery: a realistic approach?. J Aerosol Med Pulm Drug Deliv 2012, 25:249-260.
47. Krammer F., Schinko T., Messner P., et al. Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. J Virol Methods 2010, 167:17-22.
48. Vandenheuvel D., Singh A., Vandersteegen K., et al. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur J Pharm Biopharm 2013, 84:578-582.
49. Garcia-Contreras L., Wong Y.L., Muttil P., et al. Immunization by a bacterial aerosol. Proc Natl Acad Sci U. S. a 2008, 105:4656-4660.
50. Lu D., Garcia-Contreras L., Muttil P., et al. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. Aaps J 2010, 12:338-347.
51. Bivas-Benita M., Lin M.Y., Bal S.M., et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 2009, 27:4010-4017.
52. Lam J.K., Liang W., Chan H.K. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 2012, 64:1-15.